To get microscopic drug carriers swimming toward a target, German researchers took a cue from some of the best swimmers in nature: sperm cells.
Ovarian cancer cells are known to form resistance over time to chemotherapy, limiting the effect that standard cancer drugs can have on the disease. And now, researchers at Rutgers University have developed an RNA method to attack rampant proteins causing the drug resistance, allowing chemotherapy to then take out the cells.
Sanofi's Genzyme snagged a 6-month priority review from the FDA for what could become the first oral treatment for Gaucher disease, a rare genetic disorder that causes abnormal fat buildup in cells, enlarging organs in the body.
Large compounds can be difficult to push through the skin. Researchers have now developed an ultrasound technique for delivering drugs and breaking down their containers at the desired target.
To deliver large proteins past the blood-brain barrier for the treatment of Alzheimer's, researchers have developed a compound that acts as a molecular "crossing guard" for drugs to safely target brain cells and clear plaques believed to cause symptoms of the disease.
Alliqua Biomedical is a relatively small maker of hydrogel wound care and drug delivery systems looking to delve into the hot regenerative medicine space, and a recent investment from Celgene has given the company a chance at a higher profile in the arena.
Researchers at the Karolinska Institutet in Sweden have shown that omega-3 fatty acids can cross the blood-brain barrier in a potential treatment for Alzheimer's disease.
Unilife is at it again. This time it's Novartis signing a deal with the injectable technology provider, adding to Unilife's impressive list of recent agreements with top pharmaceutical companies Sanofi, MedImmune and Hikma.
Often when using nanoparticles to target and penetrate cancer cells, the shape of the tiny drug-carrying vehicles is crucial to their performance. Researchers have now found evidence that "worm-shaped" nanoparticles may be more effective than spheres at delivering cancer drugs to breast cancer.
It looks like BioDelivery Sciences is on its way to a Phase III clinical trial of its topical gel treatment for painful diabetic neuropathy following a "positive" meeting with the FDA.
Tiny, programmed drug-delivery vehicles called nanorobots have the potential to bring about more targeted treatments with fewer side effects. And a research team has built the beginnings of a DNA-based cage capable of holding and releasing drugs in such a programmed way.
At the Georgia Institute of Technology and Emory University, researchers are looking for a new way to treat rotator cuff injuries, a common baseball shoulder ailment that has ended many a star pitcher's career.
The co-founders of Bind Therapeutics, which includes MIT professor and entrepreneur Robert Langer, published new data for its targeted nanoparticle platform called Accurins, which are designed to carry drugs to specific parts of the body to treat diseases.
After earlier this month announcing promising new data supporting its genetic treatment for hepatitis B, Arrowhead Research is moving forward with the candidate, submitting its application to begin a Phase IIa trial of ARC-520, which uses its polymer-based method to effectively deliver RNAi to the nucleus.
Focal Therapeutics is working to address the idea of targeted breast cancer therapy in a way that drug companies don't. The California outfit markets a 3-D tissue marker designed to help surgeons spot the precise site for tumor removal and subsequent delivery of radiation treatment.
Aptar Pharma has taken a major leap beyond spray pumps and inhalers. At a major November conference, it debuted prefilled, auto-injectable drug delivery technology designed to help it attract more biopharmaceutical clients.
Gene-silencing expert Alnylam is $7 million richer thanks to some positive mid-stage results for its Genzyme-licensed RNA-interference candidate, and the Cambridge, MA, company is looking to be the first to market with the difficult-to-deliver class of treatments.
Naturally occurring cell materials called bionanocomposites could hold clues to the creation of hybrid natural-synthetic drug delivery systems with high degrees of biodegradability. And researchers from the Polytechnic Institute of New York have found key components of these nanomaterials that could help pave the way to that point.
Researchers in Finland have come up with a new application for well-known materials known as bisphosphonates that includes a possible role for drug delivery.
Unilife took another big step this week, signing a long-term contract agreement with generics maker Hikma Pharmaceuticals to use Unilife's injectable technology and netting up to $40 million in the process.